

Selvita

R&D pipeline news

SEL24 moves to clinic; Nodthera established

Selvita announced last week that the FDA has accepted the initial new drug application (IND) for its lead R&D project SEL24, which can now proceed to Phase I/II in acute myeloid leukaemia (AML) patients. This is the first of Selvita's R&D assets to be tested in the clinical study that the company intends to begin in Q416, in line with our expectations (H216), while the design of the trial has not yet been disclosed. Upcoming H116 report to be released on 30 August will provide an update on the company's operational performance. Our valuation is under review.

Year end	Revenue (PLNm)	PBT* (PLNm)	EPS* (PLN)	DPS (PLN)	P/E (x)	Yield (%)
12/14	41.6	5.4	0.56	0.0	43.9	N/A
12/15	56.1	7.6	0.84	0.0	29.3	N/A
12/16e	66.9	5.8	0.44	0.0	55.9	N/A
12/17e	76.5	8.7	0.63	0.0	39.0	N/A

Note: *PBT and EPS are normalised, excluding exceptional items and share-based payments.

First-in-class, most advanced, dual PIM/FLT3 inhibitor

SEL24 is a first-in-class compound with a dual mechanism of action to target two kinases, namely PIM (1, 2 and 3 isoforms) and FLT3 mutants, which have been shown to be important in the development of AML and other haematological malignancies. With its mechanism of action, SEL24 is the first compound to progress to Phase I/II. Selvita said previously that the FDA asked for supplemental preclinical information, which now has been delivered and shows a good working relationship between the company and the regulatory agency, in our view.

Innovative asset financing with Nodthera

In July 2016, Selvita, together with Epidarex Capital announced the formation of a new company, Nodthera, headquartered in Edinburgh, Scotland. Nodthera centres on NLRP3 inflammasome inhibitors, a first-in-class technology developed internally by Selvita. While it is still at an early preclinical stage with few details released, inflammasome's role in immune system response and its modulation is an emerging field that has potential across several indications with high unmet need, such as cancers and non-malignant diseases like diabetes, rheumatoid arthritis and Alzheimer's disease. Epidarex is a specialist, early-stage life sciences investor and we find the solution to carve out the asset and fund the research together with specialist investors as innovative with the potential to speed up the preclinical development in Selvita's portfolio.

Valuation: PLN363m or PLN27.0/share under review

Our previous valuation of Selvita was PLN363m or PLN27.0/share and assigned a probability of success of 7.5% for SEL24 to reach the market, which is now under review. We look forward to H116 results due shortly and will revise our forecasts and valuation subsequently.

Pharma & biotech

22 August 2016

Price **PLN24.60**
Market cap **PLN330m**

Net cash (PLNm) at end Q116	29.6
Shares in issue	13.4m
Free float	45%
Code	SLV
Primary exchange	WSE
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	12.3	9.9	36.3
Rel (local)	11.9	9.9	45.7
52-week high/low		25.8	66.0

Business description

Selvita is a drug discovery services provider based in Poland. It employs c 352 staff (30% with PhDs) and operates two main business units: the Innovations Platform (internal NME pipeline) and Research Services (medicinal chemistry/biology, biochemistry).

Next events

H116 results	30 August 2016
SEL24 Phase I start	Q416

Analysts

Jonas Peculis	+44 (0)20 3077 5728
Lala Gregorek	+44 (0)20 3681 2527

healthcare@edisongroup.com
[Edison profile page](#)

**Selvita is a research client of
Edison Investment Research
Limited**

Exhibit 1: Financial summary

	PLN'000s	2013	2014	2015	2016e	2017e
Year end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS						
Revenue		21,914	41,557	56,077	66,862	76,456
of which: Services (research outsourcing)		9,812	16,121	25,612	33,279	41,598
Innovation pipeline funding		3,241	12,744	15,416	17,817	18,320
Subsidies		8,688	12,430	14,700	15,424	16,195
EBITDA		(146)	7,626	10,235	9,262	12,792
Operating Profit (before GW and except.)		(2,228)	5,272	6,802	5,823	8,729
Intangible Amortisation		0	0	0	0	0
Exceptionals/Other		0	0	(4,729)	(5,860)	(583)
Operating Profit		(2,228)	5,272	2,073	(37)	8,146
Net Interest		(198)	155	748	14	10
Exceptionals/Other		0	0	0	0	0
Profit Before Tax (norm)		(2,427)	5,427	7,550	5,838	8,739
Profit Before Tax (reported)		(2,427)	5,427	2,821	(22)	8,156
Tax		(19)	(45)	(5)	0	(245)
Deferred tax		0	468	3,417	0	0
Profit After Tax (norm)		(2,445)	5,850	10,962	5,838	8,495
Profit After Tax (reported)		(2,445)	5,850	6,233	(22)	7,912
Average Number of Shares Outstanding (m)		10.5	10.5	13.1	13.3	13.4
EPS - normalised (PLN)		(0.23)	0.56	0.84	0.44	0.63
EPS - reported (PLN)		(0.23)	0.56	0.48	(0.00)	0.59
Dividend per share (PLN)		0.0	0.0	0.0	0.0	0.0
BALANCE SHEET						
Fixed Assets		7,067	9,494	16,718	18,279	17,716
Intangible Assets		282	331	2,274	2,274	2,274
Tangible Assets		4,932	6,845	8,597	10,158	9,595
Other		1,854	2,318	5,847	5,847	5,847
Current Assets		11,191	17,310	48,524	40,639	48,332
Stocks		391	706	1,174	1,158	1,142
Debtors		5,161	10,314	17,961	17,961	17,961
Cash		5,418	4,878	28,807	20,937	28,646
Other		221	1,411	582	582	582
Current Liabilities		(11,401)	(15,271)	(16,319)	(16,315)	(16,560)
Creditors		(3,481)	(6,055)	(3,927)	(3,927)	(3,927)
Provisions		(2,104)	(2,801)	(3,327)	(3,327)	(3,327)
Deferred revenues		(5,455)	(4,617)	(7,384)	(7,384)	(7,384)
Short term borrowings		(161)	(91)	(33)	(33)	(33)
Other		(200)	(1,708)	(1,648)	(1,643)	(1,888)
Long Term Liabilities		(3,454)	(2,278)	(2,043)	(2,043)	(2,043)
Long term borrowings		0	0	0	0	0
Deferred revenues		(3,222)	(2,010)	(1,513)	(1,513)	(1,513)
Other long term liabilities		(232)	(268)	(529)	(529)	(529)
Net Assets		3,403	9,254	46,880	40,561	47,445
CASH FLOW						
Operating Cash Flow		(7,198)	(4,902)	(16,430)	(18,288)	(4,987)
Net Interest		0	0	0	0	0
Tax		0	0	0	(4)	0
Capex		(2,167)	(3,610)	(5,190)	(5,000)	(3,500)
Acquisitions/disposals		0	0	0	0	0
Financing		0	0	27,314	0	0
Dividends		0	0	0	0	0
Other (incl. subsidies)		9,567	7,972	18,354	15,424	16,195
Net Cash Flow		202	(540)	24,049	(7,868)	7,708
Opening net debt/(cash)		(5,192)	(5,257)	(4,787)	(28,773)	(20,904)
HP finance leases initiated		0	0	0	0	0
Exchange rate movements		0	0	0	0	0
Other		(137)	71	(63)	(1)	0
Closing net debt/(cash)		(5,257)	(4,787)	(28,773)	(20,904)	(28,612)

Source: Edison Investment Research, Selvita

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Selvita and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2016. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.